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ENGINEERED IMMUNE CELL CONSORTIUM 
KATRI J. SOFJAN 
ABSTRACT 
 The endogenous immune system is a complex consortium of cells which must 
interact to effectively detect and respond to threats. Communication between cells, either 
through direct contact or by secreted chemokines and cytokines, is integral to the immune 
system’s function. The ability to rewire these communications and program coordinated 
behavior in a multicellular immune network would open new doors in the field of cell 
therapies for cancer and other diseases, as well as enabling investigation of the design rules 
for cell consortia. Previous efforts to engineer population-level immune cell behavior have 
largely been limited to secretion of soluble factors, which are nonspecific actors and do not 
enable directed communication between specific cell types. Here, we develop a framework 
for user-specified communication between engineered immune cells. We design and 
construct genetic circuits which enable the secretion of the adaptor molecule for a split 
CAR system in an activation-dependent manner, enabling modulation of the function of 
nearby cells. This novel cell to cell communication system enables programming of 
interactions between immune cells and provides a framework for the construction of 
complex cellular consortia. 
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CHAPTER ONE 
Introduction 
Predictably programming complex behavior in living cells remains a major goal of 
synthetic biology. While high level computation and logic have been engineered at the 
single cell level, control over consortium level behavior remains a challenge. Many natural 
biological systems, such as the human immune system, are able to perform complex 
integration of different signals and cell types in order to sense and respond to 
environmental cues. The immune system is an intricate organization of different cell types 
which perform specialized functions in order to detect threats and defend the body from 
them. Each cell type must identify particular inputs and execute specific outputs in order 
for the immune system to collectively address problems. Additionally, immune cells must 
communicate to synchronize complex population level responses. The ability to reprogram 
such a sophisticated system holds enormous promise for treating disease. While 
coordinated behavior has previously been engineered in microbial systems (Muller 2017, 
Tamsir 2011) and mammalian tissue organization architectures (Toda 2018), no such 
system has been developed using immune cells. Immune cells have successfully been 
engineered at the single cell level (Maude 2014), however, programming consortium level 
behavior and directing communication between immune cells has yet to be achieved.  
Immune cell engineering at the single cell level 
 Previous efforts to engineer immune cells have largely centered on the development 
of chimeric antigen receptors (CARs), which consist of an extracellular antigen binding 
domain fused to intracellular T cell signaling domains. CARs have been developed against 
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many antigens, and some have been used successfully in clinical settings to cure cancer 
(Brentjens 2013, Maude 2014).  However, CAR-T systems are fallible and subject to a host 
of problems. The CAR is fixed and non-tunable, frequently causing a too-strong response 
in which a “storm” of inflammatory factors is secreted, making the host ill (Bonifant 2016, 
Morgan 2010). Additionally, after the first administration of a CAR-T therapy, the cancer 
may downregulate the antigen which is being targeted in a phenomenon known as antigen 
escape. The engineered cells are then rendered useless against the disease (Perna 2016).  
 Some of these problems can be ameliorated by engineering CARs which execute 
logic. OR gate CARs, which can recognize multiple antigens, can circumvent antigen 
escape (Bielamowicz 2018, Grada 2013, Ruella 2016, Zah 2016). NOT gate CARs, which 
use inhibitory T cell domains to downregulate cell activation in the presence of certain 
antigens, can prevent off target effects (Fedorov 2013). Split CARs, in which binding of 
the T cell to the target cell is mediated by a bispecific engager with can recognize both cell 
types, can enable both inducibility and antigen swapping, allowing T cell function to be 
strictly regulated (Bargou 2008, Cho 2018, Kim 2015, Lohmueller 2017, Ma 2016, 
Urbanska 2012). 
 The Wong lab has developed a split, universal, and programmable (SUPRA) CAR 
system which has the potential to address some of the issues which plague CAR-T therapies 
(Cho 2018). The SUPRA CAR, depicted in Figure 1A, consists of two components: a 
universal receptor expressed on the T cell surface, and an antigen-targeting adaptor 
molecule. The receptor, called a zipCAR, consists of an extracellular leucine zipper fused 
to intracellular signaling domains. The adaptor, called a zipFv, is an scFv fused to a leucine 
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zipper which complements that of the zipCAR. The scFv binds the antigen, while the 
leucine zipper engages with the receptor on the T cells. This design allows tunable control 
over T cell activation as a function of zipFv dosage and scFv or leucine zipper affinity, and 
the enables the user to change the target antigen by swapping scFvs (Figure 1). Previous 
work in the lab has library of scFvs consisting of three orthogonal zipper pairs and scFvs 
which target four antigens. Multiple cells can be activated simultaneously by using 
orthogonal scFvs. Varying zipFv dosage or employing zipper pairs with different binding 
affinity, can modulate the strength of the response. This work offers great promise for 
refining CAR-T based therapies and provides a framework for multiplexing sense and 
respond behavior.   
 
 
Figure 1: Design elements of SUPRA system. 
SUPRA CAR’s split architecture enables superior tuning and user control over 
engineered T cells. A) Comparison of conventional CAR and SUPRA CAR. SUPRA 
CAR is composed of a zipCAR and a zipFv. The zipCAR consists of a leucine zipper 
as the extracellular domain of the CAR, the zipFv has a complementary leucine zipper 
conjugated to an scFv. B) Tunable elements of SUPRA system. SUPRA CAR’s 
strength can be tuned by modulating the strength of protein binding domains (scFv 
and leucine zipper) or toggling CAR expression or zipFv concentration. 
 
A 
 
B 
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Engineering immune cell communication 
 Attempts to engineer communication between immune cells have largely been 
limited to making CAR-T cells drive secretion of specific cytokines (Chmielewski 2011, 
Hoyos 2010, Roybal 2017). Cytokines, the base communication module of the immune 
system, are soluble proteins which cue other cells to come to a site, proliferate, attack, or 
up- or down-regulate inflammatory factors. Secretion of cytokines from engineered cells 
has enabled some degree of engagement between CAR-T cells and other immune cells 
(Chmielewski 2011, Choi 2019). However, cytokines are nonspecific actors which may 
affect the behavior many different cell types and cause a varied profile of responses. It is 
common for cytokine administration to cause severe inflammation in the host, and even 
local secretion of cytokines has been reported to cause adverse effects (Chmielewski 2014, 
Lee 2011). More problematic from an engineering standpoint is their lack of specificity: 
cytokines are paracrine actors which may act on any number of cells locally. We seek to 
develop communication channels which specifically activate certain cells. 
 We hypothesized that our recently developed SUPRA CAR system can be 
leveraged as a sense-and-respond system to enable the development of a modular, bio-
orthogonal communication framework in immune cells. We can genetically encode the 
zipFv such that it is secreted by “sender” immune cells in an activation-dependent manner, 
activating local “receiver” cells which express the complementary zipCAR. We 
demonstrate that a majority of our library of zipFvs is capable of being secreted by “sender” 
cells and activating neighboring “receiver” cells, constituting a novel intercellular 
communication channel. Then, we investigate the dynamics of the system as a function of 
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time and consortium population dynamics. Last, we show that our system can be 
implemented in primary immune cells and enables communication between different T cell 
subtypes.  
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CHAPTER TWO 
 Design and testing of a genetic circuit for inducible zipFv secretion 
 SUPRA’s unique split architecture can enable us to finely tune control over a cell 
consortium, as cells expressing orthogonal zipCARs can be induced by adding 
complementary zipFvs. However, all zipFvs must previously be expressed by HEK cells 
and purified, then added exogenously. Additionally, while several cell types could be 
controlled simultaneously in this fashion, the cell types in this situation would function 
independently. We hypothesized that the zipFv could be secreted by cells in the 
consortium, enabling us to build a second layer of communication and biocomputation onto 
the SUPRA system.  
 We developed a genetic circuit which would enable secretion of the zipFv in an 
activation-dependent manner by putting the genetic sequence coding for a zipFv under 
control of a CAR-inducible promoter. CAR activation drives transcription of cytokines and 
other cellular activation markers via several signaling pathways, including AP-1, NFκB, 
and NFAT (Frigault 2015, Macian 2005). To drive zipFv production, we selected an NFAT 
promoter consisting of a minimal IL-2 promoter preceded by 3 NFAT binding sites. The 
functional components of the zipFv are the antigen binding scFv and the leucine zipper. To 
enable secretion, we added an N-terminal Igκ2A leader sequence sourced from the 
SecTag2A vector (Invitrogen).  The architecture of this circuit is shown in Figure 2. This 
cassette was inserted into a pHR transfer vector so that it could be packaged into a lentivirus 
for viral transduction into immune cells. 
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 For the first test of the system, we selected the αHer2-EE zipFv to be secreted. 
Previous work in our lab and others have shown that the H3B1 αHer2 scFv binds strongly 
and specifically to Her2, a receptor tyrosine kinase frequently upregulated in breast, 
ovarian, lung, and other cancers.  The EE/RR zipper pair has high affinity, which enables 
strong activation of SUPRA CAR-T cells upon binding. Additionally, through previous 
studies in the lab in which soluble zipFv was purified from the supernatant of Freestyle 
HEK cells, we have seen that the αHer2-EE zipFv is secreted well. All these factors made 
αHer2-EE a promising candidate for this experiment.  
 For validation and characterization of this system, we used Jurkat T cells. Jurkat 
cells are a T cell lymphoma line which is shows a similar activation profile to CD4+ T cells 
including upregulation of the surface marker CD69 and expression of IL-2. However, 
Jurkat cells do not secrete IFNγ or exhibit cytotoxicity against target cells. Jurkat cells are 
a well-validated cell line for testing CAR expression and functionality and have previously 
been described to secrete scFv-based molecules (Choi 2019). Notably, the strain of Jurkat 
Figure 2: Genetic circuit for activation-dependent zipFv secretion. 
T cell activation results in the transcription factor NFAT translocating to the nucleus 
and binding its cognate promoter. We put the gene for zipFv production under control 
of an NFAT promoter and added a secretion tag to facilitate export of the protein.   
This circuit should enable production and secretion of soluble zipFv protein following 
T cell activation. 
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T cells used here contains with a circuit containing an NFAT promoter which drives 
expression of GFP upon cell activation. This enables us to easily read out activation using 
flow cytometry and eliminates the need for expensive and time-consuming surface marker 
staining or ELISA assays.  We hypothesized that Jurkat cells may be able to secrete zipFv 
and offer a streamlined and simple assay for characterizing cell activation.  
To test whether zipFv secretion can enable intercellular communication, the zipFv 
secretion circuit described above and depicted in Figure 2 was introduced to NFAT Jurkat 
cells bearing an αAxl CAR. These sender cells were then incubated with RR-CAR 
expressing receiver cells and target NALM6 cells expressing Axl and Her2. Figure 3 shows 
a schematic of the hypothesized communication system and the results of this experiment, 
in which 1x105 of each cell type were used.  
 
Figure 4 shows the result of this experiment. After 24 hours of coculture, receiver 
cells incubated with sender cells exhibited 10.5-fold activation over baseline. In 
Figure 3: Schematic of zipFv secretion enabling intercellular communication. 
Sender cells expressed Axl CAR and a zipFv secretion circuit enabling production of 
the αHer2-EE zipFv following activation. Receiver cells expressed a complementary 
RR-CAR. Target cells expressed Axl and Her2. Cells were cocultured at a ratio of 1 
sender: 1 receiver: 1 target, where 1 = 1x105. As a control, a condition in which sender 
cells were exchanged nonsender cells, which express Axl CAR but no zipFv secretion 
circuit, was also conducted.  
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comparison, receiver cells cocultured with “nonsenders”, or cells expressing αAxl CAR 
but not bearing the zipFv secretion circuit, were only activated 2-fold over baseline.  We 
believe that a low level of background activation may occur from nonsender cells due to 
alternative signaling pathways. For example, nonsender cells are activated by target cells 
and secrete IL-2 when activated. This IL-2 may cause low-level, non-antigen-specific 
activation of receiver cells. To account for this low-level baseline activation, as well as day 
to day variations in basal levels activation in each cell type, we will use the following 
equation to quantify the fold change of our system, which is a proxy for the efficacy of the 
communication system. 
 
 
Figure 4: zipFv secretion enables communication between Jurkat cells. 
Non or sender cells were cocultured with receiver cells. The addition of Axl+Her2+ 
target cells drove 4-fold activation of receiver cells in the sender condition compared 
to the nonsender condition, demonstrating significant activation of receiver cells as a 
result of activation-dependent zipFv secretion. (Sender cell: Axl CAR, secretes αHer2-
EE zipFv. Nonsender cell: Axl CAR. Receiver cell: RR- CAR. Target cells: 
Axl+Her2+). 
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𝐹𝑜𝑙𝑑	𝑐ℎ𝑎𝑛𝑔𝑒 = -./01-/023	24	56.60165	.677	03.89-/6:	;0/<	-./01-/6:	=63:65	.677-./01-/023	24	56.60165	.677	03.89-/6:	;0/<	-./01-/6:	323=63:65	.677
 
The system was tested 3 times over 3 separate days to evaluate the consistency and 
stability of the system. We observed that over 3 unique experiments, fold change in 
activation of receiver varied from 4.1 to 5.2-fold (Figure 5). The zipFv secretion system 
showed remarkable consistency between biological replicates. 
 
Equation 1: Fold change enables quantification of communication via zipFv 
secretion. Here, we account for basal activation of receiver cells by nonsender cells, as 
well as any background (non zipFv-dependent) interaction in order to ensure that we 
are specifically evaluating secretion-dependent activation.  
Figure 5: Intercellular communication via secreted zipFv is replicable over 3 
tests. 
The experiment depicted in Figure 3 was conducted 3 days in a row. Each bar 
represents 9 wells of pooled data, signifying 3 replicates on each of 3 separate days. 
The fold change of the system was remarkably consistent from day-to-day showing 
the replicability of this communication method. (Sender cell: Axl CAR, secretes 
αHer2-EE zipFv. Nonsender cell: Axl CAR. Receiver cell: RR- CAR. Target cells: 
Axl+Her2+). 
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The low level of receiver cell activation which was observed can be explained by 
two mechanisms. First, all the cells could have turned on 4-fold over baseline activation. 
Alternatively, some cells may be more than 4-fold activated, and some may be not activated 
at all. Examining the activation profile of the receiver cells revealed a bimodal activation 
trend (Figure 6), indicating that some cells were activated, and some were not. We attribute 
this to a combination of two factors: one, secretion is likely not robust. Only a small 
quantity of zipFv is secreted, enabling only a small population of receiver cells to turn on. 
Additionally, we believe that secretion of zipFv activates receiver cells in a local 
phenomenon.  The sender cell must have been attached to a target cell in order to be 
activated and secrete zipFv. Once this zipFv is secreted, it will likely bind to the first target 
antigen it encounters, which should be on the adjacent target cell. Experiments were 
conducted in 96-well V-bottom plates under static conditions, and after several hours the 
cells settle into the bottom of the wells. Thus, in order to be activated by the secreted zipFv, 
the target cell would need to be adjacent to a sender cell-target cell complex. This geometric 
constraint results in only a subpopulation of the receiver cells being activated. 
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Antigen specificity is a necessary characteristic of native and engineered immune 
cells and systems. If a system is not antigen specific it can have deleterious off target 
effects: in clinical applications, it may result in undesirable cell killing. In our system, lack 
of antigen specificity may result in incorrect logic being performed. To verify that the zipFv 
secretion communication channel is antigen specific, the same sender and receiver cells 
were cocultured with target cells that were either wild type, Axl+, or Axl+Her2+. When wild 
type target cells are used, neither sender nor receiver cell should be activated. Axl+ target 
cells should only activate sender cells. Axl+Her2+ target cells should activate both sender 
and receiver cells. As seen in Figure 7, results were as expected, further validating zipFv 
secretion as an antigen-dependent intercellular communication system. 
Figure 6: Receiver cells exhibit a bimodal activation profile. 
Following coculture with sender (blue) or nonsender (grey) and target cells, receiver 
cells show bimodal expression of a GFP activation marker, consistent with low levels 
of zipFv being produced by the system. (Sender cell: Axl CAR, secretes αHer2-EE 
zipFv. Nonsender cell: Axl CAR. Receiver cell: RR- CAR. Target cells: Axl+Her2+). 
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Next, we tested whether we could initiate zipFv secretion from a sender cell 
activated by a SUPRA CAR rather than a canonical CAR. SUPRA is weaker than 
traditional CARs in many cases, and it requires an additional logic step to be computed 
correctly before the receiver cell can be activated. We developed sender cells which 
expressed FOS zipCAR. Instead of being constitutively activated by target cells, these 
sender cells would be induced by addition of an αHer2-SYN9 zipFv, which pairs with FOS. 
Receiver cells expressed SYN1 zipCAR, which is complementary to the SYN2 zipFv. A 
schematic of this communication architecture is shown in Figure 8. We also wanted to 
verify that receiver cells were only activated when a matching zipFv is secreted. To test 
this, we engineered sender cells to secrete either a matching αAxl-SYN2 zipFv or a 
mismatched αAxl-SYN5 zipFv. Receiver cells should only be activated if the sender cell 
recognizes its target antigen and secretes a matching zipFv. As seen in Figure 9, we 
observed that the mismatched zipFv did not activate the receiver cell above baseline. 
However, when the matching zipFv was secreted, receiver cells were activated 2-fold 
above baseline. This demonstrates that zipFv secretion can be initiated by the SUPRA CAR 
when a receiver-activating zipFv is added, and that communication via zipFv secretion is 
dependent on receiver cells expressing the target antigen. 
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Figure 7: Activation of receiver cells is antigen-dependent. 
A) Sender and nonsender cells, which express Axl CAR were activated by all Axl+ 
cells. B) receiver cells were activated only when incubated with sender cells and 
Axl+Her2+ target cells. This further validates that zipFv secretion is responsible for 
the communication between sender and receiver cells, as activation of the nonsender 
or sender in the absence of the receiver cell’s target antigen is insufficient to drive 
receiver activation. The cell lines used for this experiment were described in Figure 3. 
(Sender cell: Axl CAR, secretes αHer2-EE zipFv. Nonsender cell: Axl CAR. Receiver 
cell: RR- CAR. Target cells: wild-type, Axl+, or Axl+Her2+ where shown). 
A 
 
B 
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Figure 8: Schematic of zipFv secretion initiated by SUPRA system. 
By using orthogonal zipper pairs, we can control activation of 2 cell types 
simultaneously. Here, sender cells and nonsender express FOS CAR and are activated 
by addition of an αHer2-SYN9 zipFv (“input zipFv”). Sender cells secrete αAxl-
SYN2 (matching) or αAxl-SYN5 (mismatched) zipFv. Receiver cells express SYN1 
CAR, which is complementary to SYN2 zipFv. We should see activation of receiver 
cells only when input zipFv is added and the matching (αAxl-SYN2) zipFv is 
secreted. 
Figure 9: Communication via zipFv secretion is dependent on leucine zipper 
pairing. 
Cell lines described in Figure 8 were cocultured in the presence or absence of target 
cells. As expected, the zipFv secretion system does not enable communication when a 
mismatched zipFv, which binds the target cell antigen but not the receiver cell 
zipCAR, is secreted.  
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Finally, we screened a panel of zipFvs for ability to activate receiver cells when 
secreted. Our library of zipFvs consists of scFvs for 4 surface antigens – CD19, Mesothelin 
(Meso), Axl, and Her2 – conjugated to any of 4 zipFvs - EE, SYN2, SYN5, or SYN9. The 
complementary zippers RR, SYN1, SYN6, and FOS, respectively, are used for the 
zipCAR. The library consists of 12 zipFvs, shown in Table 1. All zipFvs were tested for 
ability to activate receiver cells after secretion by sender. For this experiment, different 
types of sender cells were employed. We ensured that the secreted zipFv was orthogonal 
to the activation machinery for the sender cell: it would not recognize the same antigen as 
the sender cell or bear the sender cell’s cognate zipper. 
For SYN2 and SYN5 zipFvs, sender cells expressed SYN9 CAR and were activated 
by αHer2-SYN9 zipFv, in the case of αAxl zipFv secretion, or αAxl-SYN9 zipFv in the 
case of αHer2 zipFv secretion. For SYN9 and EE zipFvs, sender cells expressed SYN1 
CAR and were activated by αCD19-SYN2 zipFv. The results of this screen are shown in 
Table 1. Of 12 tested zipFvs, 10 were able to activate receiver cells over 1.5-fold. Trends 
were consistent with previously observed characteristics of zipFv strength: those zipFvs 
which we have seen secrete well and activate strongly drove higher activation of receiver 
cells than those which are weaker. This screen demonstrated that the zipFv secretion 
system is generalizable across zipFvs and zipCARs, and that a number of orthogonal 
zipFvs can be used for this system. 
Here we showed that zipFv secretion is an effective strategy for engineering cellular 
communication enabled by the structure of the SUPRA system.  
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zipper scFv Fold change 
EE 
⍺Her2 5.2 ⍺Meso 2.8 ⍺CD19 2.4 
SYN2 
⍺Axl  4.9 ⍺Her2 2.0 ⍺Meso 1.7 ⍺CD19 1.4 
SYN5 
⍺Her2 4.8 ⍺Axl 1.7 ⍺CD19 1.2 
SYN9 ⍺Her2 1.9 ⍺Meso 1.6 
 
Table 1: screen of zipFvs for activation of receiver cells. 
10 out of 12 zipFvs are able to activate receiver cells 1.5-fold following secretion from 
sender cells. 
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CHAPTER THREE 
The SUPRA CAR system is set apart from canonical CARs by its tunability. Figure 
1 showed aspects of the SUPRA CAR which can be toggled to modulate activity of the 
zipCAR expressing cell. We hypothesized that the zipFv secretion system may have other 
tunable components which could be investigated. These are depicted in Figure 10. From 
this range of potential inputs, we chose to investigate the effects of time, and sender to 
receiver cell ratio on receiver cell activation. In each case, we continued to use receiver 
cell activation, measured by GFP expression, as the readout assay. 
 
We believed that increasing the ratio of sender cells to receiver cells would increase 
the mean activation level of the receiver cells, as having more sender cells present to secrete 
zipFv increases the amount of zipFv available to activate receiver cells. For this 
Figure 10: Tunable elements of the zipFv secretion system. 
By toggling the parameters described here, we may be able to have more finely tuned 
control over the activation of the receiver cell. In this study, we chose to examine the 
effects of toggling the density of each cell type. 
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characterization, we used Jurkat cell lines in which sender cells expressed an αAxl CAR 
and secreted αHer2-EE zipFv when activated. Receiver cells expressed RR zipCAR. Target 
cells were Axl+Her2+ (see Figure 3 for reference). We cocultured cells for 24 hours at 
sender-to-receiver (S:R) cell ratios ranging from 1:9 to 9:1, as shown in Figure 11A. As 
expected, at low S:R, activation of the receiver cell was not significantly above activation 
of the receiver cell by a nonsender. As S:R increased, receiver cell activation was 
amplified. The highest receiver cell activation was observed at S:R of 3:1.  
We suggest that this may be due to a crowding effect at the 9:1 ratio. In these 
experiments, the total number of sender and receiver cells was 2x105, and the number of 
target cells was 1x105. In order for the receiver cell to be activated, a sender cell must 
secrete a zipFv. At an S:R of 1:1, each sender cell was also in 1:1 proportion to target cells. 
However, as S:R increases, there are fewer target cells available per sender cell. Since 
sender cells are constitutively able to bind target cells and receiver cells are not, by the time 
the zipFv is secreted the target cells may already be engaged with sender cells, leaving no 
extra binding area for receiver cells to bind and become activated.  
To test this theory, we repeated the experiment with twice the number of target 
cells, shown in Figure 11B. In this case, we observed that a S:R of 9:1 yielded higher 
activation of receiver cells. Our data is consistent with higher S:R yielding higher receiver 
activation, as long as sufficient antigen is available. 
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Figure 11: Higher ratio of sender cells to receiver cells yields higher receiver 
activation, barring antigen scarcity. 
A) Sender, receiver, and target cells were cultured such that sender + receiver = 2x105, 
and target = 1x105. Receiver activation increased as S:R increased, except at very high 
S:R, where target cell density became limiting. B) By doubling the target cell density, 
we enabled high S:R to drive increased activation for all tested ratios.  At high S:R, 
addition of target cells to increase antigen availability ameliorates crowding effects 
seen at lower target cell levels. The cell lines used for these studies are described in 
Figure 3 (Sender cell: Axl CAR, secretes αHer2-EE zipFv. Nonsender cell: Axl CAR. 
Receiver cell: RR- CAR. Target cells: Axl+Her2+.) 
A 
 
B 
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Next, we chose to investigate dynamics of the system over time. Many immune 
processes are dependent on the intricate temporal coordination of cells, in which one cell 
type initially recognizes an injury or pathogen and recruits other cells to the area of interest. 
We sought to quantify the delay in activation between sender and receiver cells. 
Furthermore, we hypothesized that by varying the S:R ratio we could modulate this delay.  
We cocultured αAxl CAR sender cells, RR zipCAR receiver cells, and target cells 
in various ratios (total sender and receiver cells = 2x105, target cells held constant at 1x105). 
Data points were taken at 0, 8, 12, 16, 24, 32, and 48 hours. As seen in Figure 12, we see 
that a higher S:R ratio yields significantly higher receiver cell activation. Sender cells begin 
to show signs of activation (>1.5-fold over no target cell condition) as early as 8 hours. 
Receiver cells showed signs of activation beginning at 12 hours for each condition. The 
highest activation level for each condition was observed at 32 hours. We were able to 
successfully modulate the mean level of activation of receiver cells from 2.7-fold over 
baseline in the low S:R condition to 10.3-fold over baseline with high S:R. 
We were also interested in determining whether tuning S:R would enable us to tune 
the amount of time between when the sender cell shows activation and when the receiver 
cells become activated, as a high S:R should yield more zipFv secretion and a faster 
receiver cell activation. To quantify the dynamics of the system, we calculated the rate of 
increase in receiver cell activation by measuring the slope of the activation curve during 
the period of time where activation was increasing linearly (8-32 hours). This 
quantification is shown in Table 2. We observe that for sender cells, the activation rate is 
approximately 190 GFP a.u./hour for all S:R, with the no target cell case yielding the 1.7 
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GFP a.u./hour. Lower S:R yields a slightly faster activation rate because there is less 
competition for target cells, but the activation rate is relatively consistent for sender cells 
across all conditions. This is not the case for receiver cells. Receiver cells exhibit a minimal 
activation rate when no target cells are present or when they are cocultured with nonsender 
cells instead of sender cells. However, when cocultured with sender cells there is a dramatic 
increase in the activation rate as S:R increases. At an S:R of 1:1, activation increases at a 
rate of 33 GFP a.u./hour, while at 5:1 it increases at 112 GFP a.u./hour, or over 3 times 
faster. Therefore, by modulating the ratio of sender to receiver cells, we can effectively 
dictate the rate at which receiver cells will become activated.  
 
Condition Rate of activation (a.u. GFP/hour) 
Sender cell 
activation 
no target 1.7 
1:1 206.4 
3:1 199.9 
5:1 186.1 
Receiver cell 
activation 
no target 0.6 
nonsender 3.1 
1:1 32.9 
3:1 71.4 
5:1 112.9 
Table 2: Modulating sender-to-receiver ratio enables tuning of activation rate. 
 Here, we investigated the effects of time and population dynamics on the output of 
the zipFv secretion system. We show that as long as antigen is plentiful, increasing the 
ratio of sender cells to receive cells increases the activation of the receiver cell population. 
We observe that there is approximately a four-hour lag between sender cell activation and 
receiver cell activation and determine that by changing S:R we are able to modulate the 
rate at which receiver cells become activated.  
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Figure 12: Evaluation of sender-to-receiver ratio on each species' activation over 
time. 
Sender:Receiver ratio trends are consistent across a 48-hour timeframe. Sender 
activation is consistent over S:R, while receiver activation varies significantly as S:R 
changes. Maximal receiver activation occurs at high S:R after 32 hours of coculture. 
(Sender cell: Axl CAR, secretes αHer2-EE zipFv. Nonsender cell: Axl CAR. Receiver 
cell: RR- CAR. Target cells: Axl+Her2+.) 
A 
B 
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CHAPTER FOUR 
Endogenous immune functions require a variety of cell types communicating to 
orchestrate complex spatiotemporal sense-and-respond functions. We sought to explore 
some features of endogenous immune networks using our zipFv secretion system. We 
hoped that we would be able to employ primary T cells as both sender and receiver cell 
types. We aimed to demonstrate that different T cell types (primary CD4+, primary CD8+, 
and Jurkat cells) could be engineered to interact via our synthetic communication channel. 
Additionally, we hoped to show that sender cells could secrete two zipFvs at once, enabling 
communication with two distinct populations of receiver cells. 
Our first objective was to show at CD4+ human primary T cells could act as sender 
cells and receiver cells. To test this, we transduced primary cells to express either αAxl 
CAR (nonsender cells), αAxl CAR and αHer2-EE zipFv secretion circuit (sender cells), or 
RR zipCAR (receiver cells). We tested the CD4+ cells’ ability to act as either the sender 
or the receiver, using Jurkat cells to occupy the other role. For these experiments, CD69 
expression was used as the metric for activation of the receiver cell. CD69 is a well-
documented surface marker for early activation known to be expressed by CD4+, CD8+, 
and Jurkat T cells. Cells were stained for CD69 expression after 24 hours of coculture using 
an anti-CD69 antibody which was measured via flow cytometry. As seen in Error! 
Reference source not found., we observed that CD4+ sender cells were able to activate 
Jurkat receiver cells 2.9-fold, while Jurkat sender cells were able to activate CD4+ receiver 
cells 1.7-fold. This confirmed that primary T fulfill the role of sender cells, and that the 
amount of zipFv secreted by sender cells is sufficient to activate primary receiver cells.   
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Next, we desired to show that primary CD8+ T cells could be used as receiver cells. 
CD8+ T cells are cytotoxic “killers” responsible for destroying cancerous or otherwise 
damaged cells. We sought to implement our system using CD8+ cells firstly because of 
Figure 13: CD4+ primary T cells can act as sender or receiver cells. 
A) CD4+ sender cells activated Jurkat receivers 2.9-fold. B) Jurkat sender cells 
activated CD4+ receivers 1.7-fold. (Sender cell: Axl CAR, secretes αHer2-EE zipFv. 
Nonsender cell: Axl CAR. Receiver cell: RR- CAR. Target cells: Axl+Her2+.) 
A 
 
B 
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their therapeutic usefulness, and secondly to demonstrate that the zipFv secretion system 
enables communication between different types of primary immune cells in vitro. We 
selected the “receiver” role for CD8+ cells because CD8+ cells are much harder to 
transduce than CD4+ cells. Engineering sender cells requires transduction with two 
lentiviruses, as well as selection with puromycin. CD4+ cells, which are hardier and easier 
to transduce, were used as sender cells.  
 
Following coculture of sender cells, receiver cells, and target cells for 24 hours, we 
observed that CD69 expression on CD8+ receiver cells was upregulated 2-fold, as shown 
in Figure 14. This demonstrated that the zipFv secretion system enables robust 
communication between different subsets of primary human immune cells. In addition to 
activation, we hoped to observe a functional measure of CD8+ activation. For this, we 
Figure 14: zipFv secretion enables communication between primary immune 
cell types. 
CD4+ sender cells activated CD8+ receiver cells 2-fold. (Sender cell: Axl CAR, 
secretes αHer2-EE zipFv. Nonsender cell: Axl CAR. Receiver cell: RR- CAR. 
Target cells: Axl+Her2+.) 
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measured secretion of IFNγ from sender, nonsender, and receiver cells alone and compared 
it to IFNγ levels following coculture of receiver cells with senders or nonsenders. This data 
is shown in Figure 15, left 3 data sets. As expected, receiver cells did not show increased 
cytokine production when cocultured with target cells in the absence of a sender or 
nonsender cell. Sender and nonsender cells showed 9.5 and 8.5-fold activation respectively, 
with activated sender cells producing 1.1-fold more IFNγ than activated nonsenders. As 
expected, receiver cells are upregulated <1-fold. We compared this data to the coculture 
conditions, in which the supernatant from nonsender + receiver or sender + receiver 
combinations is shown. The nonsender/receiver combination resulted in supernatant IFNγ 
very comparable to that of the nonsender alone. However, the sender/receiver combination 
was 1.8-fold higher than the sender alone and the 2.6-fold higher than the nonsender + 
receiver combination. This significant increase in cytokine production is ostensibly due to 
activation of the receiver cells by sender cells.  This data demonstrates that zipFv secretion 
enables communication between different types of immune cells resulting not only in 
expression of activation markers, but also in cytokine secretion. 
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Lastly, we desired to show that a single sender cell could secrete 2 zipFvs 
simultaneously, activating 2 different subsets of receiver cells. Previous work in the Wong 
lab identified 3 orthogonal pairs of zipFvs which can be used simultaneously to activate 
different cells with minimal crosstalk. For this exercise, we returned to using Jurkat sender 
and receiver cells. Figure 16A shows the cell lines constructed for this experiment: sender 
cells expressed FOS CAR and had machinery to secrete αAxl-SYN2 and αHer2-SYN5 
zipFvs. These zipFvs were selected based on the screening performed in Chapter 2 – they 
exhibited strong activation of receiver cells. Receiver cells expressed either SYN1 or SYN6 
CAR. The sender cell was activated by addition of an αMeso-SYN9 zipFv. Target cells 
expressed all three antigens. Following 24 hours of coculture, GFP expression of the 
Figure 15: Activating receiver cells via secreted zipFv results in increased 
cytokine production. 
Following coculture of nonsender or sender with receiver, IFNγ levels from sender + 
receiver condition (far left) are 2.6-fold higher than nonsender + receiver condition 
and 1.8-fold higher than any cell type alone, demonstrating activation of receiver cells. 
(Sender cell: CD4+ Axl CAR, secretes αHer2-EE zipFv. Nonsender cell: CD4+ Axl 
CAR. Receiver cell: CD8+ RR-CAR. Target cells: Axl+Her2+.) 
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receiver cells was measured via flow cytometry. As seen in Figure 16B, we observed 3-
fold activation of Receiver 1 (SYN1 CAR) and 2-fold activation of Receiver 2 (SYN2 
CAR). While these activation levels are lower than the ~4-fold activation observed when 
a single zipFv is being secreted, possibly due to saturation of the NFAT promoter, this 
demonstration of a single sender cell population activating 2 receiver cells at once holds 
significant promise for the development of more complex engineered immune networks. 
Here we demonstrated that zipFv secretion enables communication between 
various subsets of immune cells, including primary CD4+ and CD8+ T cells. We also 
showed that two zipFvs can be secreted at once, enabling the construction of a complex 
architecture in which a single sender cell, upon activation, recruits and activates two 
distinct types of receiver cells. In the future we believe that many more options can be 
explored using this system. This work provides the foundation for design and construction 
of highly customizable immune networks in which cells communicate, execute coordinated 
functions, and compute distributed logic. This study provides a starting point for the 
construction of complex engineered immune cell consortia using the unique capabilities of 
the SUPRA system. 
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Figure 16: Sender cells can activate multiple receiver cell types simultaneously. 
A) Depiction of cell lines used. B) Sender cells endowed with circuits to secrete 
multiple zipFvs are able to secrete these zipFvs and coordinate regulation of two types 
of receiver cells at once. Sender cell: Jurkat FOS CAR, activated by αMeso-SYN9 
zipFv, secretes αAxl-SYN1 and αHer2-SYN5 zipFvs. Receiver cell: Jurkat SYN1 or 
SYN6 CAR. Target cells: Meso+Axl+Her2+.) 
A 
B 
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CHAPTER FIVE 
Conclusion 
 
In this work, we have developed a novel bio-orthogonal communication channel 
for engineering interactions between immune cells. We designed a circuit for activation-
dependent production of zipFvs, which when secreted by sender cells selectively activate 
receiver cells which express the appropriate zipCAR. We screened a panel of 12 zipFvs for 
ability to enable communication in this framework and found 10 which enable activation 
of receiver cells. Further, we investigated the effects of population dynamics and time on 
the network and observed that by tuning the ratio of sender to receiver cells, the activation 
level of the receiver cell population can be modulated. We ported the system into primary 
immune cells and demonstrated communication between primary CD4+ and CD8+ T cells, 
in addition to Jurkat T cells. This communication results not only in activation of the 
receiver cells, but also upregulation of functional markers such as IFNγ. Finally, we 
demonstrated that sender cells can secrete 2 antigens at the same time, enabling activation 
of two separate populations of receiver cells simultaneously. This work is a major 
advancement over previous efforts to engineer immune cell communication, which relied 
heavily on secretion of broad-acting soluble factors such as cytokines. Our platform 
enables the user to specify which cells should interact and the direction of the interaction 
and is a foundation for the development of complex networks of immune cells.  
Future work expanding upon this study could proceed in several directions: 
increasing the number of cell types, investigating other forms of interactions, and 
expanding the logic network. Firstly, the system could be tested in other types of T cells, 
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such as γδ, Th1, Th2, or Treg to see if more diverse immune subtypes can be used to secrete 
zipFv or be activated by secreted zipFv. Other immune cell types such as NK cells or 
macrophages are also candidates for the receiver role. In addition to activation of receiver 
cells, other forms of interactions could be tested, including having a cell secrete its own 
zipFv, enabling a positive feedback loop, or having a sender cell secrete an inhibitory zipFv 
for a receiver cell, resulting in downregulation rather than activation of the receiver cell. 
Lastly, more complex logic networks could be constructed by implementing multiple 
sender cells each interacting with different receiver cells. The zipFv communication 
framework is robust and highly customizable, enabling a wide variety of potential 
population architectures to be investigated. 
This work provides a foundation for the construction of complex engineered 
immune consortia. We believe that further investigations which expand on this work 
through 1) optimization of zipFv production, 2) thorough investigation of the factors which 
affect cell-to-cell communication through this synthetic channel, 3) expand the cell types 
which can be used as senders or receivers, and 4) design and build more complicated 
network topologies, such as multi-stage cascades or distributed logic, will enable the 
development of cell consortia which can communicate to coordinate population-level 
responses to a range of problems. The construction of such consortia may be impactful not 
only for future development of cellular networks in vitro, but also for application to 
complex health problems such as wound healing, autoimmune disease, and cancer. 
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